WHO’s Working for Health 2022–2030 Action Plan

By Staff Writer

February 6, 2023

Introduction:

Achieving universal health care (UHC) is a World Health Organisation (WHO) strategic priority, with the goal of 1 billion more people benefitting from universal health coverage by 2025. This publication on health and care workforce planning provides a rationale for the related actions of the Working for Health progression model.

The Need for Planning and Financing:

Planning and financing are integral to the efficient and cost-effective development of health and care workforce policies. Their importance is particularly evident in low- and middle-income countries (LMICs), where technical and institutional capacity to support planning and financing is often inadequate. In such strained economic environments, building this capacity is a priority.

The Working for Health Model:

The Working for Health progression model offers a pathway for countries facing critical workforce challenges to progressively optimise, build, and strengthen their workforce. The model focuses on three key themes: planning and financing, education and employment, and protection and performance.

The Current Context:

The COVID-19 pandemic has highlighted the need for effective planning and strategic financing in the health and care workforce. LMICs face challenges such as building labour market demand for health and care workers, mobilising sufficient and sustainable revenue, and attracting and retaining workers within the health system.

Policy Landscape:

The WHO Global Strategy presents a range of policy options to advance the health and care workforce agenda. These options emphasise the need to strengthen the integration and synergy of health workforce policy with broader development strategies.

Challenges:

The COVID-19 pandemic has had a devastating impact on economies worldwide. Financial resources allocated to health and care workforce are constrained by the economic crises facing many countries. In addition, many countries lack the technical and institutional capacity to translate evidence-based information into policy development and implementation.

Future Directions:

The challenges faced by the health and care workforce require strategic planning and financing. Investment in the health and care workforce is critical in emergency and disaster risk management, building the resilience of the health system to shocks and surges in demand.

Conclusion:

The health and care workforce is a vital component of the healthcare ecosystem. As such, it is essential to invest in strategic planning and financing to ensure its growth and sustainability. By doing so, we can ensure a resilient health system capable of meeting the needs of populations worldwide.

 

 

Reference url

Recent Posts

HPV vaccine cost-effectiveness
       

Cost-Effectiveness of Switching to the Nonavalent HPV Vaccine in the Netherlands

💡 Are we ready to enhance public health with a vaccine upgrade?

Our latest review examines the cost-effectiveness of transitioning from the bivalent HPV vaccine (2vHPV) to the nonavalent HPV vaccine (9vHPV) in the Netherlands. The findings indicate that this switch could lead to significant improvements in health outcomes and disease prevention. Dive into the details of this impactful research!

#SyenzaNews #HealthEconomics #Healthcare #CostEffectiveness #PublicHealth

GLP-1 receptor risks
     

GLP-1 Receptor Agonists: Balancing Benefits and Risks in Treatment Decisions

🔍 Are GLP-1 receptor agonists really worth the risk?

Our latest analysis jumps into the potential thyroid cancer risk associated with GLP-1RAs, alongside other safety concerns.

With the complexities of treatment decisions in diabetes management, it’s crucial to prioritize individualized approaches.

Explore the full insights to understand how to weigh benefits against risks for optimal patient outcomes.

#SyenzaNews #Healthcare #Pharmaceuticals #MarketAccess #Innovation

dual immunotherapy thyroid cancer
   

Promising Dual Immunotherapy for Anaplastic Thyroid Cancer

🧬 How can dual immunotherapy reshape the treatment landscape for anaplastic thyroid cancer?

Our latest article delves into groundbreaking findings from a phase 2 trial assessing the effectiveness of nivolumab and ipilimumab in treating aggressive thyroid cancers. With promising response rates in anaplastic thyroid cancer (ATC), this innovative approach could pave the way for better outcomes. Discover the nuances of this study and its implications for personalized cancer therapies.

#SyenzaNews #oncology #clinicaltrials #immunotherapy #CancerTreatment #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.